 Surface Oncology NASDAQ: SURF has entered into a clinical trial collaboration with Roche Holdings AG OTC: RHHBY to evaluate formers SRF388, anti-IL-27 antibody, in combination with Roches atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma HCC. Atezolizumab plus bevacizumab has been shown to improve overall survival significantly and is the new standard of care for unresectable or metastatic HCC. 